Stockscreener 앱 받기
2.17
4.82%
-0.11
시간 외 거래:
2.14
-0.03
-1.38%
전일 마감가:
$2.28
열려 있는:
$1.895
하루 거래량:
74.01M
Relative Volume:
8.45
시가총액:
$529.00M
수익:
$22,000
순이익/손실:
$-190.89M
주가수익비율:
-2.4994
EPS:
-0.8682
순현금흐름:
$-149.63M
1주 성능:
-19.63%
1개월 성능:
-9.58%
6개월 성능:
+70.87%
1년 성능:
+48.63%
1일 변동 폭
$1.85
$2.175
1주일 범위
$1.85
$4.46
52주 변동 폭
$0.8621
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.17 | 555.81M | 22,000 | -190.89M | -149.63M | -0.8682 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 재개 | Jefferies | Buy |
| 2026-01-09 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene Therapeutics Prices Large Common Stock Offering - TipRanks
ALLO Maintained by Jefferies -- Price Target Raised to $10.00 - GuruFocus
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? - Yahoo Finance
ALLO Stock Slumps As $175M Secondary Offering Hits Tape - timothysykes.com
ALLO Stock Slides As $175M Equity Offering Hits Tape - StocksToTrade
[8-K] Allogene Therapeutics, Inc. Reports Material Event - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) to Sell 87.5M Shares at $2.00 - Stock Titan
Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings - Benzinga
Jefferies raises Allogene stock price target to $10 on trial data By Investing.com - Investing.com South Africa
Jefferies raises Allogene stock price target to $10 on trial data - Investing.com
Allogene publishes preclinical data for autoimmune CAR T therapy - Investing.com
Autoimmune drug candidate cleared B and T cells in lupus models - Stock Titan
Allogene Therapeutics Prices $175 Million Public Offering - marketscreener.com
Allogene Therapeutics Shares Slide on Up to $201.3M Public Offering - Moomoo
Allogene Therapeutics prices $175M stock offering at $2 per share - MSN
Biotech Allogene sells 87.5M shares at $2 to raise $175M - Stock Titan
ALLO Seeks Capital with a New Offering Below Previous Close - GuruFocus
Allogene prices $175 million stock offering at $2 per share By Investing.com - Investing.com South Africa
ALLO Maintained by Argus Research -- Price Target Raised to $3.8 - GuruFocus
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - Bitget
Allogene Therapeutics, Inc. Prices Public Offering of 87.5 Million Shares at $2.00 per Share - Quiver Quantitative
Allogene prices $175 million stock offering at $2 per share - Investing.com
Allogene Therapeutics announces pricing of public offering of common stock - marketscreener.com
Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock - TradingView — Track All Markets
Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com
ALLO Maintained by Citizens -- Price Target Raised to $8.00 - GuruFocus
ALLO Maintained by HC Wainwright & Co. -- Price Target Raised to $12 - GuruFocus
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study - TradingView — Track All Markets
ALLO Maintained by Baird -- Price Target Raised to $9.00 - GuruFocus
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
Allogene Therapeutics Stock Soars 12% On Positive Phase 2 Data For Lymphoma Treatment - TIKR.com
H.C. Wainwright raises Allogene stock price target on trial data - Investing.com UK
H.C. Wainwright raises Allogene stock price target on trial data By Investing.com - Investing.com Australia
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Bernstein raises Allogene stock price target on trial data By Investing.com - Investing.com India
Bernstein raises Allogene stock price target on trial data - Investing.com UK
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Allogene Therapeutics (ALLO) Plans $175M Stock Offering - GuruFocus
Allogene Therapeutics, Inc. Files Form 8-K Current Report with SEC on April 13, 2026 2 - Minichart
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell LymphomaSlideshow (NASDAQ:ALLO) 2026-04-14 - Seeking Alpha
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock - Bitget
Why Allogene Therapeutics (ALLO) Is Up 16.8% After Early ALPHA3 MRD Clearance Data And What's Next - simplywall.st
Allogene's off-the-shelf CAR-T strikes at residual lymphoma cells in Phase II win - FirstWord Pharma
Allogene (ALLO) Reports Positive Interim Analysis from Pivotal A - GuruFocus
Citizens raises Allogene stock price target on trial data strength By Investing.com - Investing.com Australia
Citizens raises Allogene stock price target on trial data strength - Investing.com UK
Allogene Therapeutics announces proposed public stock offering and suspends existing sales agreement - Investing.com South Africa
Cellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-cel - TipRanks
Allogene Therapeutics plans $175 million stock offering By Investing.com - Investing.com India
ALLO Stock Jumps As Traders Target ALPHA3 Trial Catalyst - timothysykes.com
Allogene Therapeutics stock hits 52-week highhere's why - MSN
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):